Robert F Graziano

Learn More
CD30 is a promising target for antibody-based immunotherapy of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma. To overcome the limitations from currently available murine anti-CD30 monoclonal antibodies (mAbs), a new fully human anti-CD30 antibody was generated. Binding properties were evaluated by recombinant CD30 capture enzyme-linked(More)
Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/ IPH2102) in a preclinical xenograft tumor model Natural Killer cells (NK cells) are lymphocytes able to recognize and kill tumors for which the expression of Major Histocompatibility Complex (MHC) class I molecules is altered. This " missing self " recognition is mediated in(More)
  • 1